Hyaline-membrane disease, alkaline buffer treatment, and cerebral intraventricular halphaemorrhage.
In 55 preterm infants dying from hyaline-membrane disease (H.M.D.) in 1971-74, infants with associated cerebral intraventricular haemorrhage (H.M.D./I.V.H.) had been given more intravascular sodium-bicarbonate solution, but the same proportions of cases with H.M.D. and H.M.D./I.V.H. received bicarbonate at the time of birth. Much of the sodium-bicarbonate solution given to H.M.D./I.V.H. infants was injected in response to the clinical effects of I.V.H. Maximum serum-sodium concentrations correlated with sodium-bicarbonate dosage but not I.V.H. The incidence of I.V.H. in preterm infants in 1971-74 was unchanged from 1956-59 when alkaline buffer treatment was not used. These findings do not suggest that sodium-bicarbonate therapy plays a major part in the pathogenesis of I.V.H.
D001639:Bicarbonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001724:Birth Weight; D001777:Blood Coagulation; D002021:Buffers; D002245:Carbon Dioxide / Q000097:blood; D002543:Cerebral Hemorrhage / Q000209:etiology*; D005260:Female; D005865:Gestational Age; D006801:Humans; D006819:Hyaline Membrane Disease / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006955:Hypernatremia / Q000150:complications; D007231:Infant, Newborn; D008297:Male; D010100:Oxygen / Q000097:blood; D011247:Pregnancy; D012964:Sodium / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use
D001639:Bicarbonates; D002021:Buffers; D002245:Carbon Dioxide; D012964:Sodium; D010100:Oxygen